Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 17/20 | 0.79 |
| ▸ | FNTB | P49356 | 17/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16792274 | 0.88 | FNTA (1.00) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL7506651 | 0.84 | FNTA (0.74) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL10652875 | 0.83 | GRIA4 (0.74) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792125 | 0.82 | GRIA4 (0.78) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792247 | 0.81 | GRIA4 (0.67) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792049 | 0.79 | FNTA (0.57) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792138 | 0.79 | FNTA (0.82) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792214 | 0.78 | FNTA (0.77) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16798046 | 0.78 | FNTA (0.82) | FNTAFNTBKMT2A | |
| SCHEMBL18151964 | 0.78 | FNTA (0.80) | FNTAFNTBKMT2AGRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | GGPS1, FDPS, COASY | FNTA 4/4885FNTB 15/4885KMT2A 4161/4885 |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | GGPS1, FDPS, COASY | FNTA 4/4885FNTB 10/4885KMT2A 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.